------------------------------------------------------------
[link removed]


** Feb 19 Webinar: HVTN 702 updates and next steps
------------------------------------------------------------
February 13, 2020

Dear Advocate,

Last week, leaders of HVTN 702 HIV vaccine efficacy trial in South Africa (also known as Uhambo), announced ([link removed]) that vaccinations would be stopped early because the vaccine candidate did not prevent HIV. Importantly, there were no safety concerns. Since then, conversations have ensued—at local and global levels—to understand the result and its implications for the future of HIV vaccine development.

AVAC ([link removed]) and Advocacy for the Prevention of HIV and AIDS (APHA ([link removed]) ) invite you to join us for a global webinar on Wednesday, February 19 at 9am EST / 4pm South Africa for the latest updates on these conversations and a reflection on how they may impact HIV prevention globally.

REGISTER HERE ([link removed]) .

The call will provide civil society perspectives from APHA and the Vaccine Resource Advocacy Group (VARG ([link removed]) ), updates from HVTN 702 researchers, and broader context of HIV vaccine development from the United States NIH ([link removed]) ’s Division of AIDS (DAIDS ([link removed]) ).

HVTN 702 is one of several Phase III vaccine trials ongoing at this time ([link removed]) . HVTN 705/ HPX2008 ([link removed]) (Imbokodo), HVTN 706/HPX3002 ([link removed]) (Mosaico) and the PrEPVacc Study ([link removed]) are all exploring novel HIV vaccine candidates. Broadly neutralizing antibodies and additional ARV-based prevention options are also in large-scale trials. Though the failure to find efficacy with HVTN 702 represents a disappointment, unflagging momentum in research must continue. It’s crucial to understand these results and the scientific contribution they will make to a future, urgently needed vaccine.

See AVAC’s updated infographics for a visual picture of the pipeline of research on biomedical HIV prevention:
* The Years Ahead in Biomedical HIV Prevention Research ([link removed])
* HIV Vaccine Research Pipeline ([link removed])
* Vaccine Efficacy Trials Pipeline ([link removed])

For additional background on the HVTN 702 trial, check out the HVTN’s fact sheet ([link removed]) .

As always, please be in touch with any questions (mailto:[email protected]) , and we look forward to Wednesday’s discussion!

Best,
AVAC

============================================================
Forward This Issue Do you know someone who might be interested in receiving this newsletter?
** Forward > ([link removed])

Unsubscribe You're receiving this because you signed up for our newsletter. Not interested any longer?
** Unsubscribe > ([link removed])

Contact Us T: +1 212 796 6423
E: ** [email protected] (mailto:[email protected])
W: ** www.avac.org ([link removed])
** ([link removed])
** ([link removed])
** ([link removed])